Product category:
Laboratory and scientific professional organisations
News Release from: Cancer Research UK | Subject: Spear prodrugs
Edited by the Laboratorytalk Editorial
Team on 29 November 2005
$8.5 million to fund cancer drug
development
The most advanced clinical candidates will be applicable to any tumour expressing the enzyme CYP1B1 and as such are directly relevant to the major cancers including breast, lung and prostate
Cancer Research Technology (CRT), Bloomsbury Bioseed Fund (BBSF), De Montfort University (DMU) and the Gray Cancer Institute announce that US venture capital firm Advent International has invested $8.5million in Spear Therapeutics CRT, DMU, BBSF and the Gray Cancer Institute (GCI) established Spear Therapeutics to drive the development of a novel class of anti-cancer therapeutics
This article was originally published on Laboratorytalk on 10 Dec 2003 at 8.00am (UK)
Related stories
New test could prevent more cervical cancer
A new test could be a more effective early warning system for preventing cervical cancer than the traditional smear according to Cancer Research UK scientists
The new class of cancer drugs arose from research carried out at both DMU and GCI, which was supported by Cancer Research UK.
The portfolio of compounds are prodrugs that are designed to be selectively activated by cancer cells, thereby minimising damage to normal tissues.
The most advanced clinical candidates will be applicable to any tumour expressing the enzyme CYP1B1 and as such are directly relevant to the major cancers including breast, lung and prostate.
Marios Fotiadis of Advent International said: "We are excited for the opportunity to advance a novel class of anti-cancer therapies developed by Spear.
"The structure of this investment allows us to focus our efforts and resources on the clinical development of these novel agents.
"We expect that this financing will allow Spear to produce meaningful clinical data".
Spear Therapeutics expects the first of its prodrugs to progress into clinical trials in late 2006.
• Cancer Research UK: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
